Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05438342	TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis	Phase Not Applicable	Date Added 2022-06-29	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Chemotherapy，checkpoint immunotherapy, targeted therapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05611034	TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung	Phase Phase 1	Date Added 2022-11-09	Location Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs oxaliplatin	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05479812	TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-07-29	Location Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Minnesota, United States New Jersey, United States New York, United States Oregon, United States Texas, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Pembrolizumab, WTX-124	Tags MSI-H/ MMRd
NCT ID NCT05487235	TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-08-04	Location Argentina Australia Brazil Canada Korea, Republic of New Zealand	Prior IO Allowed Yes	CRC-directed No	Status Completed	Drugs Atezolizumab, GDC-1971, Omeprazole	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05491317	TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors	Phase Phase 1, Phase 2	Date Added 2022-08-08	Location France	Prior IO Allowed Yes	CRC-directed No	Status Terminated	Drugs Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05493683	TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer	Phase Phase 2	Date Added 2022-08-09	Location China,China,China,China,China,China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Disitamab vedotin, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05328908	TitleA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2022-04-14	Location Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan	Prior IO Allowed No	CRC-directed Yes	Status Terminated	Drugs Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Tags MSS/ MMRp
NCT ID NCT05673148	TitleTesting the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study	Phase Phase 3	Date Added 2023-01-06	Location Arizona, United States California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Chemotherapy	Tags MSS/ MMRp
NCT ID NCT05425940	TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)	Phase Phase 3	Date Added 2022-06-21	Location Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary New Zealand Poland Portugal Singapore South Korea Spain Taiwan Thailand United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq	Tags MSS/ MMRp
NCT ID NCT05627635	TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2022-11-25	Location California, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin	Tags MSS/ MMRp

Showing 141 to 150 of 299 entries